Mei Pharma Stock Price, News & Analysis

MEI Pharma, Inc. (NASDAQ: MEIP) is described in its public disclosures as a pharmaceutical company and clinical-stage oncology business with a portfolio of drug candidates that may offer novel and differentiated cancer therapies. According to multiple company announcements, its pipeline has included voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Earlier descriptions and prior public information also reference additional oncology candidates such as pracinostat, an oral HDAC inhibitor, and ME-401 (formerly PWT143), an oral PI3K delta inhibitor, as part of the company’s development-stage portfolio.

MEI Pharma has historically focused on the clinical development of therapies for cancer, evaluating its drug candidates in oncology indications and, as stated in its own "About MEI Pharma" sections, seeking to build value through development, strategic partnerships, out-licensing and, where appropriate, commercialization arrangements. The company’s disclosures emphasize that its drug candidates are intended to be novel and differentiated, targeting mechanisms such as kinase inhibition and mitochondrial metabolism that are relevant to hematologic and solid tumors.

Beginning in mid-2024, MEI Pharma’s board of directors initiated a formal evaluation of strategic alternatives, as described in a series of press releases. The company reported that it was considering options such as out-licensing opportunities for existing programs and potential merger and acquisition transactions, with an explicit goal of maximizing the value of its assets for stockholders. In connection with this process, MEI Pharma implemented cash preservation measures, including a staged reduction-in-force and the discontinuation of clinical development of voruciclib, while continuing certain non-clinical activities related to its drug candidates.

As this strategic review progressed, MEI Pharma also reported changes in its operational focus. In a later phase, the company announced a significant shift toward a digital asset treasury strategy centered on Litecoin (LTC). Through a private placement transaction, the company raised capital with the stated intention to use the net proceeds to acquire Litecoin as its primary treasury reserve asset. Subsequent disclosures and SEC filings indicate that MEI Pharma completed this private placement and deployed the proceeds to acquire a substantial Litecoin position, describing itself as the first U.S.-listed public company to adopt Litecoin as a primary reserve asset.

In connection with this transition, MEI Pharma entered into an asset management relationship with GSR, a digital asset and treasury management advisor, to oversee the implementation of its Litecoin-focused treasury strategy. Public statements explain that this strategy is built on digital asset infrastructure and long-term capital planning, positioning Litecoin as a core component of the company’s treasury reserve framework. The company has also described its intention to expand its business model beyond its historical drug candidate portfolio to focus on institutional-grade digital asset treasury strategies.

A material corporate milestone in this evolution is documented in an 8-K filing dated September 10, 2025. In that filing, MEI Pharma reported that it had changed its corporate name to Lite Strategy, Inc. pursuant to an amendment to its amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware. The filing further states that, effective at market open on September 11, 2025, the company’s common stock, which trades on the NASDAQ Capital Market, would cease trading under the ticker symbol MEIP and commence trading under the ticker symbol LITS. The company has indicated that this rebranding is intended to reflect its expansion into digital asset treasury management.

According to the company’s own descriptions following this change, Lite Strategy, Inc. presents itself as the first U.S.-listed public company to adopt Litecoin as its primary reserve asset. The company states that it is building a long-term corporate strategy around Litecoin as a core treasury asset and is positioning itself as a pioneer in institutional-grade digital asset treasury strategies, while also continuing to evaluate preclinical and investigational opportunities related to its remaining drug candidate pipeline, including voruciclib and zandelisib.

Throughout these developments, MEI Pharma’s earlier identity as a clinical-stage oncology company and its later identity as Lite Strategy, Inc. with a Litecoin-focused treasury strategy are both part of the historical and current context for the MEIP ticker. For investors and observers researching MEIP, it is important to recognize that the ticker symbol has transitioned to LITS and that the company’s stated business focus has broadened from pharmaceutical preparation manufacturing and oncology drug development to include, and ultimately emphasize, digital asset treasury management.

Because the company has been engaged in a strategic alternatives process and has undergone a rebranding and ticker change, users should treat MEIP as the historical trading symbol for what is now Lite Strategy, Inc. Information about the company’s oncology pipeline, strategic review, and Litecoin treasury strategy all form part of the background for understanding how the business has evolved over time.